This trial is asking people with blood cancer who need a bone marrow transplant to join, to find new ways of preventing severe side effects.
- Blood Cancers
- Myeloid Leukemia
1 Primary · 4 Secondary · Reporting Duration: 1 year post transplant
2 Treatment Groups
1 of 2
1 of 2
32 Total Participants · 2 Treatment Groups
Primary Treatment: ArmA- Lymphoid · No Placebo Group · Phase 2
Who is running the clinical trial?
Age Any Age · All Participants · 21 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has ArmA-Lymphoid received regulatory authorization from the FDA?
"Given that ArmA-Lymphoid is a Phase 2 trial, and thus lacks evidence of efficacy but does have some data indicating safety, our team at Power has assigned it a score of two." - Anonymous Online Contributor
How many participants are actively engaged in this clinical experiment?
"Affirmative. Clinicaltrials.gov reflects that this clinical trial is currently enrolling patients, starting from the 4th of November 2022 and updated as recently as the 7th of November 2022. There are 32 positions available at a single medical facility." - Anonymous Online Contributor
Are there any vacancies left to join this clinical experiment?
"Affirmative. Details available on clinicaltrials.gov demonstrate that the trial, which was published on November 4th 2022 is actively enrolling individuals. Specifically, 1 research site requires 32 volunteers to participate in this project." - Anonymous Online Contributor